Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitec...

Full description

Bibliographic Details
Main Authors: Francesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, Daniele La Forgia, Deniz Can Guven, Alessandro Rizzo
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Heliyon
Subjects:
Breast cancer
Triple-negative breast cancer
ADC
Antibody-drug conjugates
Dato-DXd
Datopotamab deruxtecan
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024044165

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024044165

Similar Items